Literature DB >> 11359148

Effect of tumor necrosis factor-alpha on experimental otitis media with effusion.

D H Lee1, Y S Park, T T Jung, S W Yeo, Y C Choi, E Jeon.   

Abstract

OBJECTIVES/HYPOTHESIS: Up to the present, many reports have demonstrated that local immune response is associated with maintenance and persistence of effusion in the middle ear cavity. Resulting retention of inflammatory cells and mediators in the middle ear results in ongoing effusion. The purpose of this study was to clarify the role of tumor necrosis factor in experimental otitis media with effusion, which was induced by transtympanic injection of tumor necrosis factor in the rats. STUDY
DESIGN: Four groups were designed in two experiments. The purpose of experiment 1 was to confirm that transtympanic injection of TNF-alpha produces the middle ear effusion. In experiment 2, TNFsolRI was used to evaluate the possibility as an inhibitor in otitis media with effusion.
METHODS: The histopathological changes were observed under light microscope, and the changes in microvascular permeability were examined using Evans blue vital dye technique.
RESULTS: Middle ear effusion was developed in 70% of specimens, and histopathological changes, such as subepithelial edema and marked infiltration of neutrophils, were present in 100% at 24 hours after administration of tumor necrosis factor-alpha through transtympanic approach. Extravasation of Evans blue dye was found in all specimens injected by tumor necrosis factor-alpha, which was qualified using a fluorescence microscope and quantified using a spectrophotometer. These histopathological findings and changes in microvascular permeability were significantly reduced by tumor necrosis factor soluble receptor type I.
CONCLUSIONS: Neutrophil infiltration, subepithelial edema, increased microvascular permeability, and resultant effusion were indirectly proved to be induced by tumor necrosis factor-alpha. We hope that this study may contribute to understanding the role of tumor necrosis factor-alpha in otitis media with effusion and clarifying the future role of tumor necrosis factor soluble receptor type I in preventing otitis media with effusion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11359148     DOI: 10.1097/00005537-200104000-00030

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  6 in total

1.  Pro-inflammatory interleukins in middle ear effusions from atopic and non-atopic children with chronic otitis media with effusion.

Authors:  Beata Zielnik-Jurkiewicz; Wanda Stankiewicz-Szymczak
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-06-16       Impact factor: 2.503

2.  CC chemokine ligand 3 overcomes the bacteriocidal and phagocytic defect of macrophages and hastens recovery from experimental otitis media in TNF-/- mice.

Authors:  Anke Leichtle; Michelle Hernandez; Joerg Ebmeyer; Kenshi Yamasaki; Yuping Lai; Katherine Radek; Yun-Hoon Choung; Sara Euteneuer; Kwang Pak; Richard Gallo; Stephen I Wasserman; Allen F Ryan
Journal:  J Immunol       Date:  2010-02-17       Impact factor: 5.422

3.  Otitis Media: A Review, with a Focus on Alternative Treatments.

Authors:  L M T Dicks; H Knoetze; C A van Reenen
Journal:  Probiotics Antimicrob Proteins       Date:  2009-03-04       Impact factor: 5.265

4.  TNFA deletion alters apoptosis as well as caspase 3 and 4 expression during otitis media.

Authors:  Joerg Ebmeyer; Anke Leichtle; Michelle Hernandez; Umay Ebmeyer; Jacob Husseman; Kwang Pak; Holger Sudhoff; David Broide; Stephen I Wasserman; Allen F Ryan
Journal:  BMC Immunol       Date:  2011-01-26       Impact factor: 3.615

Review 5.  Innate signaling in otitis media: pathogenesis and recovery.

Authors:  Anke Leichtle; Yuping Lai; Barbara Wollenberg; Stephen I Wasserman; Allen F Ryan
Journal:  Curr Allergy Asthma Rep       Date:  2011-02       Impact factor: 4.806

6.  Effects of a tumor necrosis factor-α antagonist on experimentally induced rhinosinusitis.

Authors:  Dong-Hyun Kim; Eun-Ju Jeon; Shi-Nae Park; Kyung-Ho Park; Yong-Soo Park; Sang Won Yeo
Journal:  J Biomed Biotechnol       Date:  2011-06-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.